Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability Score
Oppenheimer Maintains Outperform on Design Therapeutics, Raises Price Target to $21
Design Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS results.
Design Therapeutics Q1 EPS $(0.29) Beats $(0.34) Estimate
Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15
RBC Capital Maintains Outperform on Design Therapeutics, Raises Price Target to $14
Design Therapeutics Q4 EPS $(0.27) Beats $(0.35) Estimate
Design Therapeutics shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a $18 price target.
Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says
Design Therapeutics shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $6 to $13.
RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13
RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
